New antiviral agents for the treatment of hepatitis C: ABT-450.
Open Access
- 24 January 2014
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 15 (5) , 711-6
Abstract
Introduction: Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from studies evaluating these new regimens are impressive with sustained virological response (SVR) rates of 88 – 100% after 12 weeks of therapy in patients with previously untreated HCV genotype 1 infection. SVR rates in treatment-experienced patients are also encouraging. Areas covered: Efficacy and tolerability of antiviral regimens containing ABT-450 boosted with ritonavir (ABT-450/r). Results from published studies and abstracts from recent meetings are presented. Expert opinion: Newer direct-acting antiviral agents such as ABT-450 promise effective and durable suppression of HCV with interferon/ribavirin-free all-oral regimens. This agent also allows for shorter duration of treatment and has tolerable side effects. Results of clinical trials including a broader spectrum of individuals with HCV infection are eagerly awaited.Keywords
This publication has 24 references indexed in Scilit:
- CDC and USPSTF 2012 Recommendations for Screening for Hepatitis C Virus Infection: Overview and Take-Home MessagesGastroenterology, 2013
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infectionJournal of Hepatology, 2011
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2011
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Telaprevir for Previously Treated Chronic HCV InfectionNew England Journal of Medicine, 2010
- Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin†Hepatology, 2010
- The global burden of hepatitis CLiver International, 2009
- Replication of hepatitis C virusNature Reviews Microbiology, 2007
- Fibrosis and disease progression in hepatitis CHepatology, 2002